Results 31 to 40 of about 260,498 (362)

HIV-2 Protease resistance defined in yeast cells

Retrovirology, 2006
Background Inhibitors of the HIV-1 Protease currently used in therapeutic protocols, have been found to inhibit, although at higher concentrations, the HIV-2 encoded enzyme homologue.
Raoult Didier, Audoly Gilles, M'Barek Najoua, Gluschankof Pablo   +3 more
doaj   +1 more source

Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors [PDF]

, 2017
Objectives To characterize the prevalence of transmitted drug resistance mutations (TDRMs) by plasma analysis of 750 patients at the time of HIV diagnosis from January 1, 2013 to November 16, 2016 in the Veneto region (Italy), where all drugs included in
Alvarez, M, Andreis, S, Andreoni, M, Antonelli, G, Basso, M, Boldrin, C, Cruciani, M, Dal Bello, F, Ferretto, R, Francavilla, E, Manfrin, V, Mengoli, C, Palù, G, Panese, S, Parisi, Sg., Rossi, Mc, Sarmati, L, Scaggiante, R, Turriziani, O   +18 more
core   +1 more source

HIV Protease Inhibitors Disrupt Lipid Metabolism by Activating Endoplasmic Reticulum Stress and Inhibiting Autophagy Activity in Adipocytes

PLoS ONE, 2013
Background HIV protease inhibitors (PI) are core components of Highly Active Antiretroviral Therapy (HAART), the most effective treatment for HIV infection currently available.
B. Zha, Xiaoshan Wan, Xiaoxuan Zhang, Wei-bin Zha, Jun Zhou, M. Wabitsch, Guangji Wang, V. Lyall, P. Hylemon, Huiping Zhou   +9 more
semanticscholar   +1 more source

Noninvasive High-Throughput Single-Cell Analysis of HIV Protease Activity Using Ratiometric Flow Cytometry

Sensors, 2013
To effectively fight against the human immunodeficiency virus infection/ acquired immunodeficiency syndrome (HIV/AIDS) epidemic, ongoing development of novel HIV protease inhibitors is required.
Rok Gaber, Andreja Majerle, Roman Jerala, Mojca Benčina   +3 more
doaj   +1 more source

HIV-1 Protease: Structural Perspectives on Drug Resistance

Viruses, 2009
Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms
Irene T. Weber, Johnson Agniswamy
doaj   +1 more source

Modulation of the LDL receptor and LRP levels by HIV protease inhibitors

Journal of Lipid Research, 2003
Inhibitors of the human immunodeficiency virus (HIV)-1 protease have proven to be effective antiretroviral drugs. However, patients receiving these drugs develop serious metabolic abnormalities, including hypercholesterolemia.
Huan Tran, Susan Robinson, Irina Mikhailenko, Dudley K. Strickland   +3 more
doaj   +1 more source

A folding inhibitor of the HIV-1 Protease

, 2005
Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can control AIDS. The folding of single domain proteins, like each of the monomers forming the HIV-1-PR homodimer, is controlled by local elementary ...
Abkevich, Andrade, Baldwin, Broglia, Broglia, Broglia, Broglia, D. Provasi, F. Vasile, G. Ottolina, G. Tiana, Hansen, Haspel, Ishima, Ishima, Karplus, Lesk, Leuthardt, Levy, Louis, Louis, Maritan, Panchenko, R. A. Broglia, R. Longhi, Richards, Srinivasan, Tiana, Tiana, Tiana, Todd, Tomasselli, Tomaszek, Wallqvist, Xie, Yamazaki   +35 more
core   +1 more source

HIV protease inhibitors and obesity [PDF]

Current Opinion in Endocrinology, Diabetes and Obesity, 2010
To review the current scientific literature and recent clinical trials on HIV protease inhibitors and their potential role in the pathogenesis of lipodystrophy and metabolic disorders.HIV protease inhibitor treatment may affect the normal stimulatory effect of insulin on glucose and fat storage.
Erdembileg, Anuurad, Andrew, Bremer, Lars, Berglund   +2 more
openaire   +2 more sources

Adaptive HIV-1 evolutionary trajectories are constrained by protein stability [PDF]

, 2017
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance remains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations.
Kandathil, Shaun M., Lovell, Simon C., Olabode, Abayomi S., Robertson, David L.   +3 more
core   +2 more sources

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

European Journal of Medical Research, 2009
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj   +1 more source